Platelet Aggregation and Cyclic Nucleotide Phosphodiesterase Activity in Arteriosclerotic Patients^[*]

Summary

Although roles of cyclic AMP and cyclic GMP in platelets are thought to be important on platelet aggregation, little information on their phosphodiesterase (PDE) is available. Cyclic AMP and cyclic GMP hydrolytic activities of platelets (cAMPPDE and cGMPPDE in platelets) and platelet aggregation by ADP and adrenaline were measured in 22 healthy volunteers, 26 arteriosclerotic patients and other 20 miscellaneous patients excluding vascular diseases. Activities of cAMPPDE and cGMPPDE of platelets were 2.37±0.52, 7.23 ± 1.84 in the healthy, 2.50±0.85, 7.53±2.60 in the arteriosclerotics and 2.38± 1.02, 6.98±2.59 pmol/min/10⁷ platelets in the miscellaneous patients, respectively. No significant difference was observed among these three groups. Platelet aggregabilities also showed no significant difference. However, there was a significant inverse correlation between the aggregability by 1 μg/ml of adrenaline and the PDE activities only in the arteriosclerotic patients. The correlation coefficients were −0.61 between the primary aggregation and cAMPPDE,−0.65 between the primary aggregation and cGMPPDE, −0.58 between the 5 min aggregation and cAMPPDE and −0.76 between the 5 min aggregation and cGMPPDE. The inverse correlation between platelet aggregation and cyclic nucleotide metabolism in circulating platelets of the arteriosclerotic patients may suggest that interaction of platelets with arteriosclerotic vessel walls would produce a certain change in platelets.

^* This is Publication No. 16 from the Tokyo Metropolitan Institute of Medical Science.

• References

• 1 Ball G, Brereton GG, Fulwood M, Ireland DM, Yates P. 1970; Effect of prostaglandin E₁ alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3′:5′-cyclic monophosphate. Biochemical Journal 120: 709
• 2 Barber AJ. 1976; Cyclic nucleotides and platelet aggregation. Effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes. Biochemica et Biophysica Acta 444: 579
• 3 Haslam RJ. 1973; Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Series Haematologica 6: 333
• 4 Haslam RJ. 1975. Roles of cyclic nucleotides in platelet function. In: Ciba Foundation Symposium 35. Biochemistry and Pharmacology of Platelets. Elsevier. Excerpta Medica; Amsterdam: 121
• 5 Hidaka H, Shibuya M. 1974; A new assay of cyclic nucleotide phosphodiesterase. Its application to human serum. Biochemical Medicine 10: 301
• 6 Hidaka H, Asano T. 1976; a Platelet cyclic 3′:5′-nucleotide phosphodiesterase released by thrombin and calcium ionophore. Journal of Biological Chemistry 251: 7508
• 7 Hidaka H, Asano T. 1976; b Human blood platelet 3′:5′-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochimica et biophysica acta 429: 485
• 8 Lüscher EF, Massini P. 1975. Common pathways of membrane reactivity after stimulation of platelets by different agents. In: Ciba Foundation Symposium 35. Biochemistry and Pharmacology of Platelets. Elsevier. Excerpta Medica; Amsterdam: 5
• 9 McDonald JWD, Stuart RD. 1973; Regulation of cyclic AMP levels and aggregation in human platelets by prostaglandin E₁ . Journal of Laboratory and Clinical Medicine 81: 838
• 10 Mills DCB, Smith JB. 1971; The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets. Biochemical Journal 121: 185
• 11 Motomiya T, and Yamazaki H. 1977. Effect of adenosine diphosphate on circulating platelet volume and aggregability in rabbit. In: Symposia of 16th International Congress of Hematology. Excerpta Medica; Amsterdam: in press
• 12 Salzman EW, Levine L. 1971; Cyclic 3′,5′-adenosine monophosphate in human blood platelets. II. Effect of N⁶-2′-0-dibutyryl cyclic 3′5′-adenosine monophosphate on platelet function. Journal of clinical Investigation 50: 131
• 13 Salzman EW. 1972; Cyclic AMP and platelet function. New England Journal of Medicine 286: 358
• 14 Sano T, Motomiya T, Yamazaki H, Shimamoto T. 1977; Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerotic patients and its prevention. Thrombosis and Haemostasis 37: 329
• 15 Vigdahl RL, Mongin Jr J, Marquis NR. 1971; Platelet aggregation. IV. Platelet phosphodiesterase and its inhibition by vasodilators. Biochemical and Biophysical Research Communications 42: 1088
• 16 World Health Organization Expert Committee on Arterial Hypertension and Ischemic Heart Disease. 1962; Preventive Aspects. World Health Organization Technical Report Series 231: 1
• 17 Yamazaki H, Kobayashi I, Shimamoto T. 1970; Enhancement of ADP-induced platelet aggregation by exercise test in coronary patients and its prevention by pyridinolcarbamate. Thrombosis et Diathesis Haemorrhagica 24: 438
• 18 Yamazaki H, Takahashi T, Sano T. 1975; Hyperaggregability of platelets in thromboembolic disorders. Thrombosis et Diathesis Haemorrhagica 34: 94